Kornimate/medical-research-clean huggingface dataset:
left atrial volume index and left atrial appendage flow velocities

Conditions: Thrombosis of Left Atrial Appendage

Summary: after obtaining a consent, bed side cardiac ultrasonography will be performed for cases undergoing transesophageal echocardiography to evaluate the correlation between left atrium volume and left atrial appendage flow velocity which can predict the thrombosis risk.

informed consent will be obtained prior to any research related procedures prior to performing the transesophageal echocardiography, 4 and a 2-chamber transthoracic images will be obtained to perform standard left atrial volumetric assessment as well as speckle tracking interrogation. both these procedures will be performed offline. the transesophageal echocardiography will be performed using available equipment with a 5- to 7-megahertz multiplane transducer and according to standard of care. all images will be acquired per american society of echocardiography guidelines and will be recorded for further analysis. the left atrial appendage will be best visualized in the 60, 90 and 110 degree imaging planes and left atrial appendage contraction velocity will be recorded by placing a pulsed wave doppler sample volume inside the proximal third of the left atrial appendage at each angle. in addition, images will be recorded using a 3-beat cycle capture to later perform offline velocity vector imaging analysis for left atrial appendage speckle tracking analysis. the transthoracic echocardiography will be performed just before the transesophageal echocardiography examination using a 2- to 4-megahertz transducer and according to standard practice guidelines. the following echocardiographic variables will be prospectively measured and calculated: left ventricle ejection fraction using simpson method, left atrial volume will be measured using biplane method and left atrium volume index is calculated based on body surface area. tissue doppler images of mitral valve annulus will be measured and pulsed wave doppler of mitral inflow velocity. study does not include follow up. study duration is up to 24 months

Eligibility criteria:
inclusion criteria: * study will include all patients 18-80 years of age and referred for transesophageal evaluation of left atrium or left atrium appendage for appropriate clinical indications, at the university of cincinnati university medical center and va medical center. exclusion criteria: * patients with either moderate to sever mitral valve disease or previous prosthetic mitral replacement. * patients with acute heart failure * history of previous left atrium appendage surgical intervention. * pregnant women
impact of integrated pet care on glycemic control and diabetes responsibility

Conditions: Type 1 Diabetes Mellitis

Summary: the goal of this clinical trial is to learn if incorporating the structured care of a pet fish into a family-based diabetes self-care routine combined with communication skills training works to improve glycemic control, blood glucose monitoring frequency and blood glucose review in early adolescents with suboptimal control of type 1 diabetes.


Eligibility criteria:
inclusion criteria: * age 10-13 years (inclusive) * diagnosis of t1dm for at least one year * fluency in english or spanish, (d) recent hba1c value 7.5% - 14% * utilization of a cgm or glucometer that links with software to enable viewing and documentation in daily report including a section to enter "notes" (i.e. cgm/software, dexcom/clarity; freestyle libre/libreview; accuchek,onetouch (glucometers)/mysugr) * current pet fish at home or willingness to obtain a pet fish if randomized to that intervention. exclusion criteria: * clinical or laboratory characteristics suggestive of type 2 dm * involvement in foster care * dual-home living situation * severe psychiatric disorders * developmental delay or cognitive impairment that make it difficult to establish consistent diabetes and pet care behaviors * current participation in another study that may impact glycemic control * hba1c \>14% (because these individuals may need a more intensive intervention than this is intended to provide) * lack of a computer or compatible cell phone for uploading cgm or glucometer data.

Keywords: type 1 diabetes
platelet rich fibrin augmented tympanoplasty versus cartilage tympanoplasty

Conditions: Chronic Suppurative Otitis Media

Summary: this study was performed to compare healing and hearing outcomes of two tympanoplasty techniques, performed for patients with total or subtotal tympanic membrane perforations. the first group underwent temporalis fascia tympanoplasty, augmented with platelet rich fibrin, while the second group underwent cartilage tympanoplasty. preoperative data, operative techniques, and postoperative outcomes were analyzed.

two groups are included. in the platelet rich fibrin augmented tympanoplasty group, a piece of temporalis fascia is harvested and used as a graft material. a layer of platelet rich fibrin is added to improve healing process. in the cartilage tympanoplasty group, a piece of cartilage is harvested from the patient concha and used for grafting. both groups will be compared in terms of healing and hearing. healing is considered successful if an intact tympanic membrane is achieved withing 12 weeks follow up period. hearing outcomes are analyzed by comparing the preoperative pure tone audiometry values with the postoperative values.

Eligibility criteria:
inclusion criteria: * adults patients older than 18 years. * chronic suppurative otitis media mucosal type with total or subtotal perforation. * inactive for 3 months. exclusion criteria: * recurrent perforation after previous tympanoplasty. * active inflammation of middle ear. * chronic suppurative otitis media epithelial type. * ossicular disruption or fixation diagnosed intraoperatively. * immunocompromised patients including uncontrolled diabetics, chronic liver and kidney diseases.
high intensity interval training and skeletal muscle insulin sensitivity

Conditions: Overweight and Obesity

Summary: this human intervention study will test if 12 weeks of supervised hiit-based intervention improves skeletal muscle nogd capacity in obese subjects.

19 overweight-obese (bmi =\> 27kg/m2), sedentary females and males aged 45-75yr will be enrolled in this study. participants will train 3 times/week under supervision during 12 weeks. before, after and during this 12-week training period, there will be multiple metabolic measurements.

Eligibility criteria:
inclusion criteria: * signed informed consent * age 45 - 75 years old * overweight to obese (bmi =\> 27kg/m2) * sedentary - subjects do not perform any regular physical activity weekly(\<3 times per week, \<150 min/week). exclusion criteria: * unstable body weight (weight gain or loss \> 3 kg in the past three months) * participation in an intensive weight-loss program or in vigorous exercise program during the last year before starting the study. * hba1c \> 6.5% and glucose clearance rate \>350 ml/kg/min (by ogtt). * previously diagnosed with type 2 diabetes * active cardiovascular disease. this will be determined by the questionnaires and by screening on medication. * use of beta-blockers * anticoagulant therapy * systolic blood pressure \>160 mmhg or diastolic blood pressure \>100 mmhg * abuse of alcohol (\> 3 units (1 unit = 10 gr ethanol) per day) * any contra-indication to magnetic resonance imaging (mri) scanning * participation in another biomedical study within 1 month before the first study visit, which may interfere with the outcomes of the present study. * use of any medication affecting the glucose homeostasis and whole body metabolism or diseases that may significantly interfere with the main aim of the study. * chronic renal dysfunction (creatinine \>2 increased (normal value 64-104 µmol/l) * subjects who do not want to be informed about unexpected medical findings during the screening / study, or do not wish that their physician is informed, cannot participate in the study. * subjects will be included only when the dependent medical doctor of this study approves participation after evaluating all data obtained during the screening.
outcome of cardiomyopathic adults admission in icu.

Conditions: Cardiomyopathies

Summary: to study the outcome of the cardiac function, and clinical status of the patiants with cardiomyopathy who are admitted in the i.c.u.

heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles, and peripheral oedema). it is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise. identification of the aetiology of the underlying cardiac dysfunction is mandatory in the diagnosis of hf as the specific pathology can determine subsequent treatment. most commonly, hf is due to myocardial dysfunction: either systolic, diastolic, or both. however, pathology of the valves, pericardium, and endocardium, and abnormalities of heart rhythm and conduction can also cause or contribute to hf. cardiomyopathies are defined by the who as diseases of the myocardium associated with cardiac dysfunction, cardiomyopathies are categorized into dilated, restrictive, hypertrophic, and unclassified based on the predominant pathophysiologic characteristics. a new category has been added to include right ventricular abnormalities. the disorders that are associated with systemic or certain cardiac diseases are called specific heart muscle diseases and include ischemic cardiomyopathy, valvular, hypertensive, inflammatory, metabolic, peripartal, general systemic disease, muscular dystrophies, neuromuscular disorders, and toxic and hypersensitivity reactions. the unclassified cardiomyopathy category includes disorders such as fibroelastosis, noncompacted myocardium, and systolic dysfunction with minimal dilation. patiant admitted in i.c.u. with heart failure who already have cardiomyopathy some patiants discharge without any comorbidies and some acquire renal failure, respiratory failure,mcs, sepsis, and some were associated with mortality . significant comorbidities associated with these hospitalizations included arrhythmias, renal failure , cerebrovascular disease, and hepatic impairment.

Eligibility criteria:
inclusion criteria: cardiomyopathic patiants admitted with heart failure diagonsed clinicaly , by echocardiograph , or by ecg. 1. dilated cardiomyopathy\[ unknown, uremic cardiomyopathy, post-partum, ishemic\]. 2. hypertrophic cardiomyopathy. 3. acute heart failure caused by a.c.s. , toxic myocardititis. exclusion criteria: 1. heart failure due to valvular heart disease. 2. heart failure caused by hypertension. 3. patiant with copd
effect of rice fortification with iron on anemia among children

Conditions: Iron Deficiency Anemia

Summary: this was a double-blind community-based trial, placebo controlled. during 16 weeks, children in the intervention group (gi, n=180) received iron fortified rice, and children in the control group (gc, n=174) received rice with placebo. anemia was considered present when hemoglobin \< 11.0g/dl. comparison of mean variation on hemoglobin between groups was accessed by using student's t-test. hemoglobin concentration improved in both groups, with mean increase of 0.42 g/dl in gi (11.28±1.23 g/dl to 11.75±1.16 g/dl, p \< 0.001), and 0.49 g/dl in gc (11.06±1.13 g/dl to 11.51±1.16 g/dl, p \< 0.001). anemia decreased (p \< 0.01) in both groups (37.8% to 23.3% in gi and 45.4% to 33.3% in gc), with no differences between them. hemoglobin increase was significantly higher in children who received total amount of iron ≥ 53.76 mg from fortified rice, compared to those who received less than this cut-off value (0.94 g/dl vs 0.39 g/dl p=0.03). the results suggest that this type of intervention can be useful in anemia control if fortified food intake is adequate.


Eligibility criteria:
inclusion criteria: * pre-school children attending public day care centers exclusion criteria: * sickle cell anemia, purpura
genetic test in detecting minimal residual disease in samples from younger patients registered on the cog-aall08b1 trial

Conditions: Leukemia

Summary: rationale: testing for minimal residual disease in blood samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment. purpose: this research trial studies a genetic test in detecting minimal residual disease in samples from younger patients registered on cog-aall08b1 trial.

objectives: * assess the feasibility of minimal residual disease (mrd) determination in pediatric b-lineage acute lymphoblastic leukemia (all) using deep sequencing of the immunoglobulin heavy chain locus. outline: archived blood and tumor tissue samples are analyzed for mdr using deep sequencing of immunoglobulin heavy chain locus. mdr quantification results are then compared with the flow cytometry reference methods used in cog studies.

Eligibility criteria:
disease characteristics: * samples from patients registered on the children oncology group (cog)-aall08b1 protocol and stored in the hematopathology laboratory at the university of washington * pretreatment and after induction therapy samples patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: b-cell childhood acute lymphoblastic leukemia untreated childhood acute lymphoblastic leukemia
myocardial injury in remifentanil-based versus sevoflurane-sufentanil balanced regimens in opcab surgery

Conditions: Ischemic Heart Disease

Summary: in patients undergoing off-pump coronary artery bypass (opcab) surgery with different anesthesia regimens: remifentanil (0.75 mcg/kg/min) and propofol (tci effect-site concentration 0.8-1.5 mcg/ml) (group -rp); remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%) (group-rs), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (tci effect site concentration 0.35-0.75 ng/ml) (group-ss), intergroup difference in the level of troponin i (c-tni) and creatinine kinase subtype-mb is determined before surgery (control), during vascular graft harvesting (harvesting), after completing graft construction (postgrafting), and one day after surgery (postoperative).

to determine the difference of myocardial injury upon using different anesthesia regimens: remifentanil-based regimen versus sevoflurane-sufentanil balanced regimen. patients undergoing off-pump coronary artery bypass (opcab) surgery are randomly allocated to get remifentanil (0.75 mcg/kg/min) and propofol (tci effect-site concentration 0.8-1.5 mcg/ml) (group -rp), remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%) (group-rs), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (tci effect site concentration0.35-0.75 ng/ml) (group-ss). intergroup difference in the level of troponin i (c-tni) and creatine kinase-mb is determined before surgery (control), during vascular graft harvesting (harvesting), after completing graft construction (postgrafting), 1 day after surgery (postoperative).

Eligibility criteria:
inclusion criteria: * patient undergoing opcab surgery * patient signed written informed consent exclusion criteria: * patient with intra-aortic balloon pump * patient with renal replacement therapy * patient wants to withdraw the participation to the study
a phase 2 study of elobixibat in adults with nafld or nash

Conditions: NAFLD; NASH

Summary: double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with nafld (nonalcoholic fatty liver disease) or nash (nonalcoholic steatohepatitis)

a total of 15 investigators at 15 sites received institutional review board (irb)/ethics committee (ec) approval to participate in this study and enrolled at least 1 participant.

Eligibility criteria:
key inclusion criteria: * have a current biopsy-confirmed nash within 6 months of screening or a suspected diagnosis of nafld/nash * screening magnetic resonance imaging-proton density fat fraction (mri-pdff) with ≥10% liver steatosis * fasting serum low density lipoprotein-cholesterol (ldl-c) \>130 mg/dl at screening, \>110 mg/dl on lipid-lowering medications key exclusion criteria: * body mass index (bmi) \<25 kg/m2 * fibrosis-4 index (fib-4) \>2.6 * any of the following laboratory abnormalities: 1. alanine aminotransferase (alt) \>5 × upper limit of normal (uln) or aspartate aminotransferase (ast) \>5 × uln 2. international normalized ratio (inr) ≥1.3, unless on anticoagulant therapy 3. total bilirubin \>uln, except with an established diagnosis of gilbert's syndrome 4. platelet count less than the lower limit of normal (lln) 5. creatinine clearance as calculated by the modification of diet in renal disease (mdrd) estimated glomerular filtration rate (egfr) equation \<60 ml/min * uncontrolled type 2 diabetes defined as hemoglobin a1c (hba1c) \>9.5% * clinical hyperthyroidism or hypothyroidism or screening hormone results pointing to thyroid dysfunction. * uncontrolled hypertension * participants with known intolerance to mri or with conditions contraindicated for mri procedures
pnf vs pertubation based balance training in subacute stroke patients.

Conditions: Stroke

Summary: to determine the effects of proprioceptive neuromuscular facilitation exercises versus perturbation-based balance training on balance, coordination, and proprioception in subacute stroke patients, it will be a randomized clinical trial.

stroke is the major cause of disability and mortality worldwide. stroke is defined as an abrupt neurological outburst caused by impaired perfusion through the blood vessels to the brain. every year the number of strokes affected individuals are rising thereby putting an extra pressure on socioeconomic conditions in developing countries. major complications of stroke include hemiplegia leading to upper limb dysfunction along with gait abnormalities. this study will be conducted to determine the effects of proprioceptive neuromuscular facilitation exercises versus perturbation-based balance training on balance, coordination, and proprioception in subacute stroke patients. the randomized clinical trial will be conducted, participants will be selected through non probability convenience sampling technique and then randomly allocated into three treatment groups.

Eligibility criteria:
inclusion criteria: * age:40-70 years. * gender: male and female * the subacute stroke patients, at least 3 months post stroke. * patients able to stand without support from upper limb. * patients able to perform 10 meter walk test. exclusion criteria: * neurological conditions other than stroke like guillain barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, parkinson's disease, transverse myelitis etc. * patients with not intact higher mental function and cognition. * patients with grade 3 arthritis and traumatic injuries like spinal cord injuries and tbis * other chronic disabling pathologies, orthopedic injuries that could impair locomotion

Keywords: hemiplegia cardiovascular accident pnf pbbt (pertubation based balance training)
copeptin and acute coronary syndrome without st-segment elevation

Conditions: Chest Pain

Summary: the purpose of this study is to determine whether the combination of copeptine and troponin adds diagnosis information to that provided by troponin alone or the combination of troponin and myoglobin. hypothesis : if the values of troponin and copeptin are not elevated, diagnosis of acute myocardial infarction can be ruled out without prolonged monitoring and serial blood sampling.

patients older than 18 years with pain suggestive of acute coronary syndrome, with onset within the last 12 hours, presenting to the emergency department of the university hospital gabriel montpied (clermont-ferrand, france) and the general hospital henri mondor (aurillac, france) are enrolled. upon admission to the hospital, all patient underwent an initial clinical assessment, including medical history, temperature, respiratory rate, cardiac frequency, blood pressure, pulse oxymetry, 18-lead ecg, chest x-ray and screening blood test including c reactive protein, natremia, troponine t, myoglobin, creatin kinase and copeptine. patients with hyponatremia \ 1 μg/l are released study. blood sampling are taken for troponine t, myoglobin, creatin kinase and copeptine analysis and 18-lead ecg was performed after 2, 4, 6 and 12 h. copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°c at each time point. the treatment of patients is not modified by the study. at 90 days, clinicals and paraclinicals events are collected.

Eligibility criteria:
inclusion criteria: * chest pain suggestive of acute coronary syndrome * chest pain with onset within the last 12 h * patients older than 18 years exclusion criteria: * st-elevation myocardial infarction * legal incapacity * sepsis * hyponatremia \< 135 mmol/l * shock * lung neoplasms * life expectancy of less than 6 months * refuse to consent

Keywords: copeptin troponin diagnosis chest pain acute coronary syndrome acute myocardial infarction unstable angina
seocalcitol versus placebo in the adjuvant treatment of hepatocellular carcinoma

Conditions: Liver Neoplasms

Summary: to evaluate the efficacy of seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (hcc).


Eligibility criteria:
inclusion criteria: * hospital in- or out patients * either sex * 18 to 75 years of age * with hepatocellular carcinoma treated successfully with surgical resection or percutaneous ablative treatment within 4 and 8 weeks, respectively, prior to inclusion. * all patients must give their signed informed consent to join the study. exclusion criteria: * patients previously treated with any anti-cancer therapy for hcc except for surgical resection and percutaneous ablative therapy * patients treated with chemotherapy or other anti-cancer therapy (except surgical resection or percutaneous ablative treatment) in the previous 4 weeks * patients with another primary tumor except basocellular carcinoma of the skin or in situ carcinoma of the cervix within the last 2 years * with a history of renal stone(s) * with a life expectancy \< 3 months * who performance status 3 or 4. * patients with hypercalcemia (ionised serum calcium \> 1.35 mmol/l or albumin corrected serum calcium \> 2.68 mmol/l), previous/current calcium metabolic disease, taking calcium-lowering therapy or medication known to affect systemic calcium metabolism, or with marked laboratory abnormalities. * patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases, okuda stage iii disease and patients with a child-pugh score of c are also excluded.

Keywords: liver cancer hepatocellular carcinoma
intrathecal morphine in knee arthroplasty

Conditions: Pain, Postoperative; Arthroplasty, Replacement, Knee

Summary: this study is designed to explore the efficacy lower doses of intra-spinal morphine for pain relief and side effect profiles of same in the setting of total knee replacement.we hypothesized that a dose greater than that used in total hip replacement was needed and wished to find a dose which was effective but had a low side effect profile.


Eligibility criteria:
inclusion criteria: * patients for elective total knee arthroplasty exclusion criteria: * no contraindication to spinal * no allergy to morphine, rescue analgesia or anti-emesis treatment.

Keywords: pain, postoperative arthroplasty, replacement, knee morphine injections, intrathecal